1. Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020
- Author
-
Hannelore Neuhauser, Angelika Schaffrath Rosario, Hans Butschalowsky, Sebastian Haller, Jens Hoebel, Janine Michel, Andreas Nitsche, Christina Poethko-Müller, Franziska Prütz, Martin Schlaud, Hans W. Steinhauer, Hendrik Wilking, Lothar H. Wieler, Lars Schaade, Stefan Liebig, Antje Gößwald, Markus M. Grabka, Sabine Zinn, and Thomas Ziese
- Subjects
Adult ,Male ,Travel ,Multidisciplinary ,Epidemiology ,SARS-CoV-2 ,COVID-19 ,Antibodies, Viral ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten ,COVID-19 Testing ,Seroepidemiologic Studies ,Viral infection ,Immunoglobulin G ,Humans ,Female ,Travel-Related Illness - Abstract
Pre-vaccine SARS-CoV-2 seroprevalence data from Germany are scarce outside hotspots, and socioeconomic disparities remained largely unexplored. The nationwide representative RKI-SOEP study (15,122 participants, 18–99 years, 54% women) investigated seroprevalence and testing in a supplementary wave of the Socio-Economic-Panel conducted predominantly in October–November 2020. Self-collected oral-nasal swabs were PCR-positive in 0.4% and Euroimmun anti-SARS-CoV-2-S1-IgG ELISA from dry-capillary-blood antibody-positive in 1.3% (95% CI 0.9–1.7%, population-weighted, corrected for sensitivity = 0.811, specificity = 0.997). Seroprevalence was 1.7% (95% CI 1.2–2.3%) when additionally correcting for antibody decay. Overall infection prevalence including self-reports was 2.1%. We estimate 45% (95% CI 21–60%) undetected cases and lower detection in socioeconomically deprived districts. Prior SARS-CoV-2 testing was reported by 18% from the lower educational group vs. 25% and 26% from the medium and high educational group (p
- Published
- 2022
- Full Text
- View/download PDF